Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
ALN-SOD in Amyotrophic Lateral Sclerosis: NCT06351592 Clinical Landscape Report 2026
15 October 2026
NCT06351592 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ALG-055009 in Metabolic Dysfunction Associated Steatohepatitis: NCT06342947 Clinical Landscape Report 2026
15 October 2026
NCT06342947 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Tislelizumab in Glioblastoma Multiforme: NCT06353360 Clinical Landscape Report 2026
15 October 2026
NCT06353360 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Empagliflozin in Metabolic Dysfunction Associated Steatohepatitis: NCT06355310 Clinical Landscape Report 2026
15 October 2026
NCT06355310 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Carboplatin in Glioblastoma Multiforme: NCT06356883 Clinical Landscape Report 2026
15 October 2026
NCT06356883 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ropidoxuridine in Glioblastoma, IDH-Wildtype: NCT06359379 Clinical Landscape Report 2026
15 October 2026
NCT06359379 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Kylo-0603 in Metabolic Dysfunction Associated Steatohepatitis: NCT06365580 Clinical Landscape Report 2026
15 October 2026
NCT06365580 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Abemaciclib in Triple Negative Breast Cancer: NCT06365788 Clinical Landscape Report 2026
15 October 2026
NCT06365788 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NX-210c in Amyotrophic Lateral Sclerosis: NCT06365216 Clinical Landscape Report 2026
15 October 2026
NCT06365216 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Triple Negative Breast Cancer: NCT06371807 Clinical Landscape Report 2026
15 October 2026
NCT06371807 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cadonilimab in Triple Negative Breast Cancer: NCT06367088 Clinical Landscape Report 2026
15 October 2026
NCT06367088 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Triple Negative Breast Cancer: NCT06371274 Clinical Landscape Report 2026
15 October 2026
NCT06371274 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.